Αποτελέσματα Αναζήτησης
13 Ιουν 2023 · Despite reducing tumor-promoting inflammation, IL-10 may have a role in rejuvenating exhausted tumor-resident T cells. Contrary to the assumption that IL-10 produces an immunosuppressive tumor microenvironment (TME), it promotes activation of tumor-resident CD8+ T cells, which aids tumor rejection.
6 Οκτ 2015 · First, we show that high level of serum IL–10 has a tight correlation with poor prognosis in cancer patients, which suggests that IL–10 is a promising biomarker for the evaluation of disease progression and survival time.
25 Ιαν 2022 · In human breast cancer, therapeutic blockade of IL-10 receptor signaling augments CD8 T-cell-dependent primary tumor response to chemotherapeutic agents such as paclitaxel and carboplatin. 48 In addition, several studies have demonstrated the inverse correlation between CD8 T cells, poor prognosis, and elevated levels of IL-10 in the tumor ...
Intratumoral T-cell deficiency and chronic inflammation have been linked independently to a poor prognosis in patients with cancer, and therapeutic approaches to overcome either pathology separately are in clinical testing.
2 Μαρ 2014 · Intratumoral T-cell deficiency and chronic inflammation have been linked independently to a poor prognosis in patients with cancer, and therapeutic approaches to overcome either pathology separately are in clinical testing.
31 Δεκ 2022 · The purpose of this review is to discuss the current understanding of the pegilodecakin (PEGylated interleukin 10) and its role in the inhibition of tumour growth and metastasis. This review also focuses on clinical data published to date that have evaluated the efficacy and safety of pegilodecakin.
13 Δεκ 2011 · By induction of IFNγ in CD8 + T cells, IL-10 induces expression of intratumoral antigen presenting molecules. This uncovers the cellular and molecular mechanisms to elicit immunological control of tumors, and delineates a strategy for treatment of late stage cancers.
